01/30/2025
Highlights of the 31st Annual PCF Scientific Retreat
PCF hosts an Annual Scientific Retreat to share the latest research findings, inspire collaboration, promote mentorship, and honor the newest awardees. Sessions at the 31st Retreat addressed basic biology and genetics research, clinical trials, new drug targets to overcome treatment resistance, the future of AI in prostate cancer, the impact. Read More
01/30/2025
For Metastatic Prostate Cancer, More is More
In this four-part series of interviews with renowned medical oncologist Neeraj Agarwal, M.D., of the University of Utah’s Huntsman Cancer Institute, we have shown that ADT alone is not sufficient in treating early metastasis (metastatic hormone-sensitive prostate cancer, or mHSPC) – and that ADT works much better when it is. Read More
01/30/2025
For Metastatic Prostate Cancer, More is More
“There is no doubt,” says medical oncologist Neeraj Agarwal, M.D., of the University of Utah’s Huntsman Cancer Institute, “that ADT alone is not sufficient” in treating early metastasis (metastatic hormone-sensitive prostate cancer, or mHSPC). “It works so much better when it is combined” with an androgen-receptor pathway inhibitor (ARPI; these. Read More
01/30/2025
For Metastatic Prostate Cancer, More is More
As we discussed in Part 1, the year 2015 was a milestone in treatment of early metastasis (metastatic hormone-sensitive prostate cancer, or mHSPC). For the first time, the CHAARTED study showed that men with mHSPC who began ADT plus chemotherapy (docetaxel) lived significantly longer than men who started treatment with. Read More
01/30/2025
For Metastatic Prostate Cancer, More is More
Many studies have shown that hitting prostate cancer hard in early metastasis with more than one treatment approach minimizes symptoms, preserves quality of life, and prolongs survival. So why aren’t more men being offered the standard of care? What is undertreatment? It’s aiming too low: undershooting the arrow and falling. Read More
01/30/2025
New Prostate Cancer Screening Study: Help Spread the Word
The PSA screening test for prostate cancer has been used for decades, but it's not a perfect test. Doctors don't yet have an optimal way to identify upfront which men are at lower risk of aggressive prostate cancer and which men are at higher risk and might need earlier and/or more frequent screening. A new study for. Read More
01/21/2025
New Resource for Patients & Families
DNA is the genetic code that tells our bodies how to grow and work. An inherited mutation (also known as an inherited cancer risk gene) is a change in a parent’s DNA that is passed down to a child. Most prostate cancers happen by chance. But for some people, different. Read More
01/21/2025
Highlights of the 31st Annual PCF Scientific Retreat
PCF hosts an Annual Scientific Retreat to share the latest research findings, inspire collaboration, promote mentorship, and honor the newest awardees. Sessions at the 31st Retreat addressed basic biology and genetics research, clinical trials, new drug targets to overcome treatment resistance, the future of AI in prostate cancer, the impact. Read More
01/17/2025
Secure Page: Young Investigator Award- Class of 2024
To view this protected post, enter the password below:Password: Read More
The Prostate Cancer Foundation (PCF) Mourns the Loss of Dr. Felix Feng
The Prostate Cancer Foundation (PCF) mourns the loss of Dr. Felix Feng, a beloved husband and father, leading physician-scientist, and cherished member of the PCF research family, who passed away on December 10, 2024, from cancer. A giant of oncology, Dr. Feng was a trailblazer in personalizing prostate cancer management. Read More